Skip to main content
Figure 3 | BMC Cancer

Figure 3

From: TTFields alone and in combination with chemotherapeutic agents effectively reduce the viability of MDR cell sub-lines that over-express ABC transporters

Figure 3

Effects of doxorubicin and paclitaxel when applied separately and in combination with TTFields on the viability of wild type and MDR cells. A - MDA-MB-231 & MDA-MB-231/Dox; B - MCF-7 & MCF-7/Mx; C - AA8 & EmtR1. Open bars - wild type cells; filled bars - MDR cell sub-lines. I & III - Separate exposures, II & IV - combined exposures. TTFields intensity - 1.75 V/cm. Doxorubicin concentrations: A - 0.04 μM; B - 0.5 μM; C - 0.6 μM. Paclitaxel concentrations: A - 5 nM; B -0.1 μM; C - 0.1 μM. Treatment duration - 72 h. Data presented as mean ± SEM of 24-36 replicate measurements from 3-5 experiments. * P < 0.01, student t-test.

Back to article page